Bayesian Hemodynamics model for personalized monitoring of congestive heart failure patients. Translating physician*s reasoning into computational models.

Bayesian Hemodynamics model for personalized monitoring of congestive heart failure patients. Translating physician*s reasoning into computational models. - Validation of a Bayesian Hemodynamics model for heart failure patiënts.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON47581

Enrollment

Registered

2019-01-15

Start date

2018-10-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure

Interventions

Bayesian

Heart failure

Hemodynamic

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: In order to be included in this study, the subject is admitted to the department of cardiology in the LUMC due to congestive heart failure.

Exclusion criteria

Exclusion criteria: A subject will be excluded from the study if he or she does not meet the inclusion criteria. Thus when the patient isn't admitted to the department of cardiology due to congestive heart failure.

Design outcomes

Primary

Measure	Time frame
Laboratory outcomes: * Na (mmol/l) * K (mmol/L) * eGFR (ml/min) * serum creatinine (micromol/L) * TSH (mu/L) * GGT (IU/litre) * AST (IU/litre) * Pro BNP (ng/L) * Lipid profile * Hb (mmol/l) 12-lead ECG * Heart rhythm * Heart rate (BPM) * QRS duration (ms) * QRS morphology (LBBB/RBBB) Transthoracic echocardiography * Limitary protocol (Left Ventricular function and dimensions, Right Ventricular function and dimensions, Mitral valve, Tricuspid valve, Inferior Vena Cava dimensions) X-thorax Physical examination * Weight (kg) * Pulse pressure; systolic, diastolic, MAP (mmHg) * Prominent neck veins * Heart rhythm, manual (irregular, regular) * Heart Sound (S3 Gallop) * Heart murmurs: (valve insufficiency) * Heart enlarged (apex * SpO2 (%) * Orthopnoea * Dyspnoea * Respiration rate (breaths/min) * Pleura fluid * Liver tender enlargement * Nausea * Pitting Edema (pretibial, bilateral) * Pitting Edema (sacral when rising in the morning) * Nocturia Questionnaire * Did your weight increase last 24h, and how much? (yes/no) Do you have more dyspnoea complains? (yes/no, if yes: 0-10 scale) Have you noticed edema? (yes/no, if yes: 0-10 scale) Do you feel fatigue? (yes/no, if yes: 0-10 scale) Do you feel nauseous? (yes/no, if yes: 0-10 scale) Have you contacted the hospital or your GP? (yes/no) Medication use * Diuretics (kind, dosage) * Inotropics (kind, dosage)	—

Measure

Time frame

Laboratory outcomes: * Na (mmol/l) * K (mmol/L) * eGFR (ml/min) * serum creatinine (micromol/L) * TSH (mu/L) * GGT (IU/litre) * AST (IU/litre) * Pro BNP (ng/L) * Lipid profile * Hb (mmol/l) 12-lead ECG * Heart rhythm * Heart rate (BPM) * QRS duration (ms) * QRS morphology (LBBB/RBBB) Transthoracic echocardiography * Limitary protocol (Left Ventricular function and dimensions, Right Ventricular function and dimensions, Mitral valve, Tricuspid valve, Inferior Vena Cava dimensions) X-thorax Physical examination * Weight (kg) * Pulse pressure; systolic, diastolic, MAP (mmHg) * Prominent neck veins * Heart rhythm, manual (irregular, regular) * Heart Sound (S3 Gallop) * Heart murmurs: (valve insufficiency) * Heart enlarged (apex * SpO2 (%) * Orthopnoea * Dyspnoea * Respiration rate (breaths/min) * Pleura fluid * Liver tender enlargement * Nausea * Pitting Edema (pretibial, bilateral) * Pitting Edema (sacral when rising in the morning) * Nocturia Questionnaire * *Did your weight increase last 24h, and how much? (yes/no) * *Do you have more dyspnoea complains? (yes/no, if yes: 0-10 scale) * *Have you noticed edema? (yes/no, if yes: 0-10 scale) * *Do you feel fatigue? (yes/no, if yes: 0-10 scale) * *Do you feel nauseous? (yes/no, if yes: 0-10 scale) * *Have you contacted the hospital or your GP?* (yes/no) Medication use * Diuretics (kind, dosage) * Inotropics (kind, dosage)

—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)